SCHEMBL6188445

SCHEMBL6188445

CCCN(Cc1cccc(Br)c1)C(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.60
HDAC6 Q9UBN7 4/20 0.60
PKM P14618 3/20 0.60
PTGES O14684 1/20 0.55
LIMK1 P53667 2/20 0.51
PPARG P37231 1/20 0.50
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
LIMK2 P53671 1/20 0.49
RIPK1 Q13546 1/20 0.48
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6186387 0.87 PTGES (0.59) HDAC1HDAC6PKMPTGESKMT2A
SCHEMBL1926269 0.85 HDAC1 (0.73) HDAC1HDAC6PKMLIMK1KMT2A
SCHEMBL6182681 0.81 KMT2A (0.69) HDAC1HDAC6PTGESKMT2AL3MBTL1
SCHEMBL13911243 0.80 LIMK1 (0.65) HDAC1HDAC6PKMLIMK1PPARG
SCHEMBL1003735 0.78 TP53 (0.68) HDAC1HDAC6LIMK1
SCHEMBL6183303 0.78 PTGES (0.62) PKMPTGESPPARGKMT2ATMEM97
SCHEMBL6508147 0.77 RIPK1 (0.51) HDAC1PKMPTGESKMT2ARIPK1
SCHEMBL94864 0.77 PPARG (0.49) HDAC1HDAC6PTGESLIMK1PPARG
SCHEMBL13911247 0.77 HDAC1 (0.66) HDAC1HDAC6PKMLIMK1KMT2A
SCHEMBL6184104 0.76 BCHE (0.53) HDAC1HDAC6PKMPTGESLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
CN-1468226-A Biphenyl derivatives and their use as ppar-gamma receptor activators �������о�����չ˽�����޹�˾ 2004-01-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD HDAC1 502/4885HDAC6 1271/4885PKM 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.